Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyinosinic-Polycytidylic Acid Injection for COVID-19
ChiCTR2000029776Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polyinosine-polycytidylic acid in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Time to clinical recovery. Started Feb 2020; status: recruiting.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000029776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029776.